类胰蛋白酶
医学
耐受性
激发试验
抗组胺药
肥大细胞
皮肤科生活质量指数
药效学
胃肠病学
免疫学
不利影响
内科学
湿疹面积及严重程度指数
临床终点
药理学
临床试验
病理
药代动力学
疾病
替代医学
作者
Dorothea Terhorst‐Molawi,Tomasz Hawro,Eva Maria Grekowitz,Lea Alice Kiefer,Kunal Merchant,Diego Alvarado,Lawrence J. Thomas,Thomas R. Hawthorne,Elizabeth M. Crowley,Margo E. Heath-Chiozzi,Martin Metz,Marcus Maurer
出处
期刊:Allergy
[Wiley]
日期:2022-11-17
卷期号:78 (5): 1269-1279
被引量:153
摘要
BACKGROUND: Chronic inducible urticaria (CIndU) is characterized by mast cell (MC)-mediated wheals in response to triggers: cold in cold urticaria (ColdU) and friction in symptomatic dermographism (SD). KIT receptor activation by stem cell factor (SCF) is essential for MC function. Barzolvolimab (CDX-0159) is a humanized antibody that inhibits KIT activation by SCF and was well tolerated in healthy volunteers with dose-dependent plasma tryptase suppression indicative of systemic mast cell ablation. METHODS: This is an open-label, trial in patients with antihistamine refractory ColdU or SD, receiving one IV dose of barzolvolimab (3 mg/kg), with a 12-week follow-up. Primary endpoint was safety/tolerability; pharmacodynamic (PD)/clinical endpoints included serum tryptase, plasma SCF, skin MC histology, provocation tests, urticaria control test (UCT), and dermatology life quality index (DLQI). RESULTS: Analysis populations were safety (n = 21) and pharmacodynamics/clinical activity (n = 20). Barzolvolimab was well tolerated; most adverse events were mild and resolved. Treatment resulted in significant depletion of skin MCs, decreased tryptase (
科研通智能强力驱动
Strongly Powered by AbleSci AI